First in Human (FIH) Study to Assess Safety and Efficacy of the CorNeat KPro for the Treatment of Corneal Blindness

Inclusion Criteria: * Male or female aged ≥ 18 and ≤ 80 years on the day of screening * Candidates must have the ability and willingness to attend all scheduled visits and comply with all study procedures * Keratoprosthesis surgery is indicated in cases when keratoplasty is not a reasonable option or following a verifiable history of prior failed corneal transplantation * Indications that fall under poor candidate for keratoplasty include but are not limited to: herpetic keratitis, vascularized corneal scar, Ocular Cicatricial Pemphigoid, alkali burn, Steven Johnson Syndrome, and limbal stem cell deficiency * Pseudophakia * Adequate tear film and lid function * Perception of light in all quadrants * Female patients of childbearing age must have negative pregnancy test at screening and agree to use an effective method of contraception throughout the study Exclusion Criteria: * Reasonable chance of success with traditional keratoplasty * Current retinal detachment * Connective tissue diseases * End-stage glaucoma * History or evidence of severe inflammatory eye diseases (i.e. uveitis, retinitis, scleritis) in one or both eyes within 6 months prior to planned implantation * History of ocular or periocular malignancy * History of extensive keloid formation * Any known intolerance or hypersensitivity to topical anaesthetics, mydriatics, or component of the device * Signs of current infection, including fever and current treatment with antibiotics * Severe generalized disease that results in a life expectancy shorter than a year * Any clinical evidence that the investigator feels would place the subject at increased risk with the placement of the device * Corneal thickness less than 400 or higher than 1,200 microns in any region of the pachymetry map of the eye intended to be operated * Currently pregnant or breastfeeding * Participation in any study involving an investigational drug or device within the past 30 days or 5 half-lives of the drug (whichever longer) or ongoing participation in a study with an investigational drug or device * Intraoperative complication that would preclude implantation of the study device * Vulnerable populations